Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fully understood and voluntarily signed the informed consent form~* With high compliance~* BMI 18.6-28.5 kg/m\^2, and with weight ≥ 50 kg for male, or ≥ 45 kg for female~Exclusion Criteria:~* Allergic to any component of study drugs, other leukotriene receptor antagonists, sulfonamides, or non-steroidal anti-inflammatory drugs~* With clinically relevantly abnormal vital sign, examination, or clinically relevant disease~* Had drug abuse within 3 months before screening or positive in drug of abuse test~* With any routine use of drugs~* Received major surgery within 6 months before study drug administration or planned to receive major surgery during study period~* With average number of cigarettes smoked \> 5/day within 3 months before screening or refused to suspend smoking from 24 hours before study drug administration throughout study period~* With average alcohol consumption \> 14 units/week within 6 months before screening or refused to suspend alcohol consumption from 24 hours before study drug administration throughout study period~* With average tea, coffee, or other drink with caffeine consumption \> 8\*250 mL/day, or refused to suspend tea, coffee, other drink with caffeine, or grape fruit juice consumption from 24 hours before study drug administration throughout study period~* Lost or donated blood \> 200 mL within 3 months, or donated platelet \> 24 U within 1 months before study drug administration~* Received any drug within 14 days before study drug administration~* Received any drug of other clinical trial within 3 months before study drug administration~* Received any vaccine within 4 weeks before study drug administration~* Planned for pregnancy within 3 months after informed consent form signed or refused to use adequate contraception (excluding contraceptive drug)~* For female, pregnant, breastfeeding, received oral contraceptives within 30 days, or contraceptive injection or implant within 6 months before study drug administration~* For pregnancy-capable female, had unprotected sexual contact within 14 days before study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TR (Type: OTHER): Administration order: montelukast sodium oral thin films with water, montelukast sodium chewable tablets with water.
- RT (Type: OTHER): Administration order: montelukast sodium chewable tablets with water, montelukast sodium oral thin films with water.

Based on this trial design, predict the completion outcome and termination type (if applicable).